Yahoo
TX45 Phase 1b trial interim analysis demonstrated meaningful improvements in both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH-HFpEF”)Positive TX45 Phase 1b interim results support endpoints and patient population in ongoing APEX Phase 2 trial, with topline results expected in 2026TX45 Phase 1b Part B trial enrolled its first subject with Heart Failure with reduced Ejection Fraction (“H
Yahoo
WATERTOWN, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that company management will participate in two upcoming investor conferences taking place in March 2025. TD Cowen 45th Annual Health Care Conference Date:March 5, 2025Time:9:50 AM ESTLocati
SeekingAlpha
Tectonic Therapeutic has done well to advance its Fc-fusion protein candidate TX45 into a phase 2 study targeting patients with PH-HFpEF. Explore more details here.
Yahoo
WATERTOWN, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), today announced that it has entered into a securities purchase agreement for a private investment in public equity financing (the “PIPE”) that is expected to result in gross proceeds of approximately $185.0 million. Pursuant to the terms of the securities purchase agreement, at the closing of the PIPE, Tectonic will issue an aggregate of 3,689,465 shares of common stock at a price of $50.0
SeekingAlpha
Tectonic Therapeutic, Inc.'s stock surged 120% on positive Phase 1b data for TX45 in treating PH-HFpEF, offering a potential opportunity. Click for more on TECX.
Yahoo
TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (“PH-HFpEF”), supporting endpoints and patient population in ongoing APEX Phase 2 clinical trialInterim analysis demonstrated that TX45 achieved 17.9% reduction in Pulmonary Capillary Wedge Pressure (“PCWP”) in the total study population of PH-HFpEF and >30% reduction in Pulmonary Vascular Resistance (“PVR”) in Combined pre- and
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
OSK | 53.98% | $6.07B | -23.62% | 2.02% |
IBM | 46.17% | $230.57B | +30.99% | 2.70% |
LVS | 38.49% | $27.66B | -27.36% | 2.19% |
ABG | 37.60% | $4.34B | -5.76% | 0.00% |
NTCT | 36.83% | $1.51B | -3.67% | 0.00% |
DLB | 36.20% | $7.74B | -3.89% | 1.57% |
ETD | 34.49% | $704.41M | -17.54% | 5.62% |
TMO | 33.49% | $187.73B | -13.83% | 0.32% |
FAT | 32.86% | $51.24M | -30.80% | 15.05% |
TWO | 32.24% | $1.39B | +1.14% | 13.49% |
IMNM | 30.57% | $585.18M | -69.56% | 0.00% |
USAC | 30.27% | $3.17B | +0.07% | 7.84% |
CALX | 29.85% | $2.36B | +9.28% | 0.00% |
PGRE | 29.65% | $935.37M | -5.49% | 0.82% |
PH | 29.47% | $78.27B | +10.32% | 1.08% |
CLS | 29.35% | $9.14B | +71.70% | 0.00% |
ONEW | 29.16% | $259.34M | -41.78% | 0.00% |
ACMR | 28.28% | $1.47B | -23.02% | 0.00% |
SEIC | 28.18% | $9.86B | +9.68% | 1.22% |
WYNN | 27.55% | $8.86B | -21.64% | 1.20% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
TYL | -<0.01% | $25.06B | +39.53% | 0.00% |
ED | -0.01% | $39.05B | +22.43% | 3.04% |
VHC | 0.02% | $31.32M | +18.43% | 0.00% |
BOX | 0.02% | $4.44B | +8.13% | 0.00% |
ASGN | 0.03% | $2.75B | -38.36% | 0.00% |
HRTG | 0.04% | $441.37M | +31.21% | 0.00% |
STTK | 0.05% | $45.36M | -89.31% | 0.00% |
HES | -0.05% | $49.24B | +3.20% | 1.21% |
MGY | -0.05% | $4.90B | -3.55% | 2.14% |
FDX | -0.06% | $58.41B | -12.98% | 2.26% |
BX | 0.08% | $170.34B | +6.68% | 2.83% |
COR | -0.09% | $53.93B | +14.44% | 0.76% |
TAL | -0.11% | $6.05B | +14.27% | 0.00% |
EB | -0.11% | $199.67M | -61.07% | 0.00% |
BIGC | 0.12% | $452.74M | -15.91% | 0.00% |
ABUS | -0.12% | $668.27M | +36.33% | 0.00% |
TMUS | 0.14% | $304.51B | +63.96% | 1.15% |
SUPN | 0.16% | $1.83B | -2.30% | 0.00% |
WDAY | 0.17% | $62.12B | -14.28% | 0.00% |
CPRI | 0.17% | $2.33B | -56.50% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -23.59% | $404.97M | 1.43% |
AFIF | -17.84% | $135.76M | 1.11% |
IBMO | -16.76% | $505.83M | 0.18% |
VIXY | -13.57% | $195.31M | 0.85% |
TAIL | -12.98% | $86.92M | 0.59% |
KMLM | -10.05% | $222.40M | 0.9% |
USDU | -7.26% | $213.46M | 0.5% |
XONE | -6.39% | $628.76M | 0.03% |
UUP | -6.05% | $327.80M | 0.77% |
CTA | -5.99% | $963.19M | 0.76% |
BILZ | -5.70% | $709.48M | 0.14% |
DBA | -5.61% | $822.16M | 0.93% |
ICSH | -5.53% | $5.66B | 0.08% |
CORN | -5.43% | $51.34M | 0.2% |
SOYB | -4.94% | $25.81M | 0.22% |
IVOL | -4.54% | $479.06M | 1.02% |
UNG | -4.30% | $434.44M | 1.06% |
TBLL | -4.20% | $2.07B | 0.08% |
FLDR | -3.65% | $774.22M | 0.15% |
AGGH | -3.63% | $313.78M | 0.29% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
CPSJ | 30.83% | $32.78M | 0.69% |
NUKZ | 28.11% | $188.52M | 0.85% |
BLOK | 27.42% | $675.28M | 0.76% |
RSPA | 27.15% | $290.25M | 0% |
GRID | 26.92% | $2.03B | 0.57% |
IPO | 26.84% | $129.98M | 0.6% |
KOMP | 26.45% | $1.95B | 0.2% |
CWB | 25.98% | $3.84B | 0.4% |
CPRJ | 25.70% | $48.46M | 0.69% |
ICVT | 25.59% | $2.56B | 0.2% |
PPI | 25.58% | $50.86M | 0.78% |
ARKG | 25.55% | $977.87M | 0.75% |
BKCH | 25.25% | $116.08M | 0.5% |
FFTY | 25.19% | $64.06M | 0.8% |
ARKK | 24.70% | $5.08B | 0.75% |
RSPF | 24.45% | $305.86M | 0.4% |
VBK | 24.35% | $17.51B | 0.07% |
FTC | 24.35% | $1.04B | 0.6% |
BLCN | 24.32% | $43.07M | 0.68% |
DAPP | 24.26% | $135.15M | 0.51% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
EQLS | -0.02% | $4.77M | 1% |
GTIP | 0.05% | $144.83M | 0.12% |
IBDZ | -0.07% | $294.40M | 0.1% |
TIPX | -0.07% | $1.65B | 0.15% |
MMIN | -0.12% | $471.66M | 0.3% |
IBTI | 0.12% | $987.96M | 0.07% |
VTIP | 0.14% | $13.61B | 0.03% |
STIP | -0.15% | $11.52B | 0.03% |
TIP | 0.16% | $14.50B | 0.18% |
SMMU | 0.18% | $680.91M | 0.35% |
IBDQ | -0.20% | $3.18B | 0.1% |
IBTF | 0.24% | $2.24B | 0.07% |
ZROZ | -0.27% | $1.57B | 0.15% |
BNO | 0.32% | $95.40M | 1% |
STPZ | 0.35% | $443.63M | 0.2% |
IBTH | -0.35% | $1.51B | 0.07% |
USO | -0.35% | $1.02B | 0.6% |
CANE | -0.37% | $11.05M | 0.29% |
UCON | -0.42% | $3.46B | 0.85% |
GOVZ | 0.43% | $288.61M | 0.1% |
Current Value
$17.771 Year Return
Current Value
$17.771 Year Return
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
UPS | -35.50% | $93.27B | -25.49% | 5.94% |
IRWD | -29.48% | $235.24M | -82.93% | 0.00% |
SIGI | -29.47% | $5.56B | -14.37% | 1.59% |
JBSS | -28.98% | $824.68M | -31.31% | 1.19% |
CMCSA | -27.34% | $139.52B | -12.72% | 3.36% |
WHR | -25.13% | $4.99B | -24.39% | 7.75% |
CI | -23.45% | $89.19B | -9.64% | 1.73% |
SCSC | -23.44% | $797.99M | -20.85% | 0.00% |
CHRW | -17.00% | $12.11B | +39.62% | 2.41% |
NOW | -16.23% | $164.96B | +3.61% | 0.00% |
MSFT | -15.74% | $2.79T | -11.58% | 0.85% |
MUR | -15.38% | $4.14B | -38.83% | 4.32% |
MSB | -15.20% | $356.86M | +49.45% | 25.34% |
AVY | -14.96% | $14.05B | -20.40% | 1.98% |
VZ | -14.03% | $190.95B | +7.28% | 5.89% |
DOW | -13.34% | $24.58B | -40.06% | 8.13% |
MVO | -13.00% | $62.10M | -50.68% | 23.99% |
MXL | -11.36% | $919.12M | -42.93% | 0.00% |
MO | -10.99% | $101.47B | +38.87% | 6.74% |
TSCO | -10.97% | $29.29B | +6.68% | 6.42% |